Certified by Founder Lodge
Digitalis Ventures
United States - New York, NY
INVESTOR
1 Disclosed Funding Rounds $100,000,000
60 Participating Investments
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
Digitalis Ventures is a venture capital firm that invests in solutions to complex problems in human and animal health. Digitalis partners with entrepreneurs, scientists, and inventors across
| Company | Date | Round | Raised |
|---|---|---|---|
T-Therapeutics Ltd |
November, 16 ,2023 | Series A | $59,707,000 |
Alpha-9 Oncology |
October, 24 ,2024 | Series C | $175,000,000 |
Ness |
May, 11 ,2022 | Seed | $15,500,000 |
GRO Biosciences |
July, 23 ,2024 | Series B | $60,300,000 |
Gallant Therapeutics |
January, 09 ,2024 | Series A | $15,000,000 |
Matchpoint Therapeutics |
October, 17 ,2022 | Series A | $100,000,000 |
Switch Therapeutics |
March, 15 ,2023 | Series A | $52,000,000 |
Companion |
April, 13 ,2023 | Unknown | $6,000,000 |
Ansel Health |
January, 24 ,2024 | Unknown | $20,000,000 |
Eden Brew |
May, 31 ,2022 | Unknown | $5,000,000 |
Alpha-9 Oncology |
October, 24 ,2024 | Series C | $175,000,000 |
Ascend Gene & Cell Therapies |
May, 10 ,2023 | Series A | $132,500,000 |
MoeGo |
March, 05 ,2024 | Series A | $24,000,000 |
Judo Bio |
October, 08 ,2024 | Seed | $100,000,000 |
Companion |
April, 13 ,2023 | Unknown | $6,000,000 |
T-Therapeutics Ltd |
November, 16 ,2023 | Series A | $59,707,000 |
Alterome Therapeutics, Inc |
April, 09 ,2024 | Series B | $132,000,000 |
Ness |
May, 11 ,2022 | Seed | $15,500,000 |
Gallant Therapeutics |
January, 09 ,2024 | Series A | $15,000,000 |
Ascend Gene & Cell Therapies |
May, 10 ,2023 | Series A | $132,500,000 |
Switch Therapeutics |
March, 15 ,2023 | Series A | $52,000,000 |
ELEGEN |
May, 16 ,2024 | Series B | $35,000,000 |
Ansel Health |
January, 24 ,2024 | Unknown | $20,000,000 |
T-Therapeutics Ltd |
November, 16 ,2023 | Series A | $59,707,000 |
Alpha-9 Oncology |
October, 24 ,2024 | Series C | $175,000,000 |
Gallant Therapeutics |
January, 09 ,2024 | Series A | $15,000,000 |
MoeGo |
March, 05 ,2024 | Series A | $24,000,000 |
GRO Biosciences |
July, 23 ,2024 | Series B | $60,300,000 |
Companion |
April, 13 ,2023 | Unknown | $6,000,000 |
Ansel Health |
January, 24 ,2024 | Unknown | $20,000,000 |
Alterome Therapeutics, Inc |
April, 09 ,2024 | Series B | $132,000,000 |
Judo Bio |
October, 08 ,2024 | Seed | $100,000,000 |
Ascend Gene & Cell Therapies |
May, 10 ,2023 | Series A | $132,500,000 |
MoeGo |
March, 05 ,2024 | Series A | $24,000,000 |
ELEGEN |
May, 16 ,2024 | Series B | $35,000,000 |
Alpha-9 Oncology |
October, 24 ,2024 | Series C | $175,000,000 |
T-Therapeutics Ltd |
November, 16 ,2023 | Series A | $59,707,000 |
Alterome Therapeutics, Inc |
April, 09 ,2024 | Series B | $132,000,000 |
Gallant Therapeutics |
January, 09 ,2024 | Series A | $15,000,000 |
Galatea Bio Inc. |
March, 28 ,2025 | Unknown | $25,000,000 |
GRO Biosciences |
July, 23 ,2024 | Series B | $60,300,000 |
ELEGEN |
May, 16 ,2024 | Series B | $35,000,000 |
Ansel Health |
January, 24 ,2024 | Unknown | $20,000,000 |
GRO Biosciences |
July, 23 ,2024 | Series B | $60,300,000 |
Judo Bio |
October, 08 ,2024 | Seed | $100,000,000 |
Judo Bio |
October, 08 ,2024 | Seed | $100,000,000 |
MoeGo |
March, 05 ,2024 | Series A | $24,000,000 |
Alpha-9 Oncology |
October, 24 ,2024 | Series C | $175,000,000 |
Alpha-9 Oncology |
October, 24 ,2024 | Series C | $175,000,000 |
Galatea Bio Inc. |
March, 28 ,2025 | Unknown | $25,000,000 |
Alterome Therapeutics, Inc |
April, 09 ,2024 | Series B | $132,000,000 |
Positive Development |
August, 07 ,2025 | Unknown | $51,500,000 |
Galatea Bio Inc. |
March, 28 ,2025 | Unknown | $25,000,000 |
ELEGEN |
May, 16 ,2024 | Series B | $35,000,000 |
GRO Biosciences |
July, 23 ,2024 | Series B | $60,300,000 |
Judo Bio |
October, 08 ,2024 | Seed | $100,000,000 |
Alpha-9 Oncology |
October, 24 ,2024 | Series C | $175,000,000 |
Galatea Bio Inc. |
March, 28 ,2025 | Unknown | $25,000,000 |
Positive Development |
August, 07 ,2025 | Unknown | $51,500,000 |
Faeth Therapeutics |
October, 21 ,2025 | Unknown | $25,000,000 |
T-Therapeutics Ltd
Alpha-9 Oncology
Ness
GRO Biosciences
Gallant Therapeutics
Matchpoint Therapeutics
Switch Therapeutics
Companion
Ansel Health
Eden Brew
Ascend Gene & Cell Therapies
MoeGo
Judo Bio
Alterome Therapeutics, Inc
ELEGEN
Galatea Bio Inc.
Positive Development
Faeth Therapeutics
Cherry Ventures
Blue Bear Capital
Slow Ventures
Climate Capital
Eniac Ventures
Sizable Energy | $8,000,000 | (Oct 24, 2025)
Sumble | $38,500,000 | (Oct 24, 2025)
Syntracts | $5,300,000 | (Oct 24, 2025)
Cybrid | $10,000,000 | (Oct 24, 2025)
Elevara Medicines | $70,000,000 | (Oct 24, 2025)